Filtered By:
Source: Circulation
Condition: Atrial Fibrillation
This page shows you your search results in order of date.
Order by Relevance | Date
Total 235 results found since Jan 2013.
Oral Anticoagulation Use and Left Atrial Appendage Occlusion in LAAOS III
CONCLUSIONS: The benefit of LAA occlusion was consistent whether patients were receiving OACs or not. LAA occlusion provides thromboembolism reduction in patients independent of OAC use.PMID:37732457 | DOI:10.1161/CIRCULATIONAHA.122.060315
Source: Circulation - September 21, 2023 Category: Cardiology Authors: Stuart J Connolly Jeff S Healey Emilie P Belley-Cote Kumar Balasubramanian Domenico Paparella Katheryn Brady Wilko Reents Bernhard C Danner P J Devereaux Mukul Sharma Chinthanie Ramasundarahettige Salim Yusuf Richard P Whitlock Source Type: research
Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease
CONCLUSIONS: Compared with 2.5 mg, use of 5 mg apixaban was associated with a higher risk of bleeding in patients with atrial fibrillation and severe chronic kidney disease, with no difference in the risk of stroke/systemic embolism or death, supporting the apixaban dosing recommendations on the basis of kidney function by the European Medicines Agency, which differ from those issued by the US Food and Drug Administration.PMID:37681341 | DOI:10.1161/CIRCULATIONAHA.123.065614
Source: Circulation - September 8, 2023 Category: Cardiology Authors: Yunwen Xu Alex R Chang Lesley A Inker Mara McAdams-DeMarco Morgan E Grams Jung-Im Shin Source Type: research
CIB2 Is a Novel Endogenous Repressor of Atrial Remodeling
CONCLUSIONS: Our data suggest that CIB2 represents a novel endogenous and atrial-enriched regulator that protects against atrial remodeling and AF under stress conditions. Therefore, CIB2 may represent a new potential target for treating AF.PMID:37128899 | DOI:10.1161/CIRCULATIONAHA.122.062660
Source: Circulation - May 2, 2023 Category: Cardiology Authors: Yihui Wang Jizheng Wang Ling Shi Xiuyu Chen Desheng Li Chen Cui Kai Yang Minjie Lu Jinhua Huang Lei Zhang Fei Li Jinxi Wang Biyi Chen Bin Wang Duane D Hall Zhenwei Pan Jiang Hong Long-Sheng Song Lei Song Shihua Zhao Source Type: research
Effects of Systematic Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: a Secondary Analysis of the Randomized LOOP Study
CONCLUSIONS: In an elderly population with additional stroke risk factors, ILR screening for AF was associated with a significant reduction in stroke risk among individuals with higher NT-proBNP levels, but not among those with lower levels. These findings should be considered hypothesis-generating and warrant further study before clinical implementation.PMID:37061802 | DOI:10.1161/CIRCULATIONAHA.123.064361
Source: Circulation - April 16, 2023 Category: Cardiology Authors: Lucas Yixi Xing S øren Zöga Diederichsen S øren Højberg Derk W Krieger Claus Graff Ruth Frikke-Schmidt Morten S Olesen Axel Brandes Lars K øber Ketil J ørgen Haugan Jesper Hastrup Svendsen Source Type: research
Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF
CONCLUSIONS: Standard-dose DOACs are safer and more effective than warfarin down to a CrCl of at least 25 mL/min. Lower-dose DOACs do not significantly lower the incidence of bleeding or ICH compared with standard-dose DOACs but are associated with a higher incidence of S/SE and death. These findings support the use of standard-dose DOACs over warfarin in patients with kidney dysfunction.PMID:37042255 | DOI:10.1161/CIRCULATIONAHA.122.062752
Source: Circulation - April 12, 2023 Category: Cardiology Authors: Josephine Harrington Anthony P Carnicelli Kaiyuan Hua Lars Wallentin Manesh R Patel Stefan H Hohnloser Robert P Giugliano Keith A A Fox Ziad Hijazi Renato D Lopes Sean D Pokorney Hwanhee Hong Christopher B Granger Source Type: research
Pharmacology and Clinical Development of Factor XI Inhibitors
This article reviews the rationale, pharmacology, results of medium or small phase 2 studies, and future perspectives of drugs inhibiting FXI.PMID:36913497 | DOI:10.1161/CIRCULATIONAHA.122.062353
Source: Circulation - March 13, 2023 Category: Cardiology Authors: Antonio Greco Claudio Laudani Marco Spagnolo Federica Agnello Denise Cristiana Faro Simone Finocchiaro Marco Legnazzi Maria Sara Mauro Placido Maria Mazzone Giovanni Occhipinti Carla Rochira Lorenzo Scalia Davide Capodanno Source Type: research
